These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24596388)

  • 1. Prolyl-isomerase Pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression.
    Yun HJ; Kim JY; Kim G; Choi HS
    Anticancer Res; 2014 Mar; 34(3):1409-16. PubMed ID: 24596388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
    Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
    Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer.
    Ryo A; Uemura H; Ishiguro H; Saitoh T; Yamaguchi A; Perrem K; Kubota Y; Lu KP; Aoki I
    Clin Cancer Res; 2005 Oct; 11(20):7523-31. PubMed ID: 16243827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1.
    Khanal P; Namgoong GM; Kang BS; Woo ER; Choi HS
    Mol Cancer Ther; 2010 Mar; 9(3):606-16. PubMed ID: 20179161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
    Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
    Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.
    Choi HJ; Kim JY; Lim SC; Kim G; Yun HJ; Choi HS
    Br J Pharmacol; 2015 Nov; 172(21):5096-109. PubMed ID: 26267432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer.
    Namgoong GM; Khanal P; Cho HG; Lim SC; Oh YK; Kang BS; Shim JH; Yoo JC; Choi HS
    J Biol Chem; 2010 Jul; 285(31):23829-41. PubMed ID: 20479004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolyl isomerase PIN1 negatively regulates SGK1 stability to mediate tamoxifen resistance in breast cancer cells.
    Jo A; Yun HJ; Kim JY; Lim SC; Choi HJ; Kang BS; Choi BY; Choi HS
    Anticancer Res; 2015 Feb; 35(2):785-94. PubMed ID: 25667458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.
    Kanaoka R; Kushiyama A; Seno Y; Nakatsu Y; Matsunaga Y; Fukushima T; Tsuchiya Y; Sakoda H; Fujishiro M; Yamamotoya T; Kamata H; Matsubara A; Asano T
    PLoS One; 2015; 10(6):e0127467. PubMed ID: 26039047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells.
    Sajadimajd S; Yazdanparast R
    Apoptosis; 2017 Jan; 22(1):135-144. PubMed ID: 27770268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prolyl isomerase Pin1 interacts with and downregulates the activity of AMPK leading to induction of tumorigenicity of hepatocarcinoma cells.
    Khanal P; Kim G; Yun HJ; Cho HG; Choi HS
    Mol Carcinog; 2013 Oct; 52(10):813-23. PubMed ID: 22549912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation.
    Lee NY; Choi HK; Shim JH; Kang KW; Dong Z; Choi HS
    Carcinogenesis; 2009 Apr; 30(4):671-81. PubMed ID: 19168580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells.
    Jin J; Zhang Y; Li Y; Zhang H; Li H; Yuan X; Li X; Zhou W; Xu B; Zhang C; Zhang Z; Zhu L; Chen X
    Neoplasma; 2013; 60(1):92-100. PubMed ID: 23067222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
    Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide.
    Mathur R; Chandna S; N Kapoor P; S Dwarakanath B
    Curr Cancer Drug Targets; 2011 Mar; 11(3):380-92. PubMed ID: 21247380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.